Loading...
XKRX
003220
Market cap130mUSD
Oct 08, Last price  
8,190.00KRW
1D
-0.73%
1Q
2.38%
Jan 2017
-48.15%
Name

Daewon Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XKRX:003220 chart
P/E
—
P/S
0.29
EPS
—
Div yield, %
3.05%
Shrs. gr., 5y
0.09%
Rev. gr., 5y
14.44%
Revenues
605.64b
+1.25%
74,356,701,00090,659,340,000115,930,546,000144,696,109,000138,874,712,510138,168,464,960158,878,874,390181,984,511,140216,187,082,890240,722,373,520265,462,478,270286,652,511,070317,827,566,520308,501,015,860354,176,435,160478,884,656,360526,952,045,064598,162,353,000605,637,117,000
Net income
-1.38b
L
7,819,323,0007,673,313,0009,761,816,00011,845,725,0009,436,354,0009,614,763,58012,320,944,75015,728,543,41017,694,916,95020,241,973,32010,742,011,29023,744,481,65027,288,953,78017,640,388,7006,988,825,61031,944,350,70023,916,930,91814,209,541,000-1,379,677,000
CFO
43.58b
+45.11%
4,870,670,00011,827,404,00010,533,572,00016,782,211,00017,932,732,18013,827,655,89012,320,481,90017,447,350,53025,816,897,80020,791,924,5804,265,009,49040,032,139,06030,970,630,74024,951,403,57022,413,390,64033,325,991,99051,734,342,12030,035,039,00043,583,762,000
Dividend
Dec 29, 2025250 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1958 and headquartered in Seoul, South Korea, Daewon Pharmaceutical Co., Ltd. is a well-regarded pharmaceutical enterprise specializing in the development, manufacturing, and distribution of a comprehensive range of medications and medical supplies within the South Korean market. Its extensive product portfolio targets diverse therapeutic fields, encompassing cardiovascular, respiratory, anti-infective, oncology, and neuropsychiatric conditions. Key offerings include Oramin-F Soft Cap, a notable multivitamin; Pelubi Tablet, an NSAID specifically formulated for pain management; Freefol-MCT Inj., a microemulsion propofol designed to prevent exogenous bacterial infections; Megex-I Susp, a medication that supports the nutritional needs of cancer patients experiencing subalimentation; Trigel Susp, an effective treatment for gastritis and duodenal ulcers; and Renamezin Cap, a spherical carbonaceous adsorbent for managing chronic kidney disease. Furthermore, Daewon Pharmaceutical extends its global footprint by exporting its products to approximately 45 countries, predominantly across Asia, Central and South America, and the Middle East.

Key people

In Baek
President, Co-Chief Executive Officer, Director · since 2024
Byeong Ho Yoon
Co-President
Hui Byeong Byun
Managing Director · since 2022
Bong Cheol Cho
Managing Director
Yeon Seop Kim
Managing Director
Ju Yil Kim
Managing Director
So Ra Lee
Managing Director · since 2020
Gyeong Jun Lee
Managing Director · since 2021
Se Yil Son
Managing Director
Han Yil Yim
Managing Director
Yin Yeong Baek
Assistant Managing Director · since 2024
Non-Executive Independent Director, Internal Auditor
Tae Gyun Cho
Assistant Managing Director
Seon Hui Gil
Assistant Managing Director · since 2025
Yeong Nam Gwon
Assistant Managing Director · since 2023
Gyeong Hun Hahm
Assistant Managing Director · since 2024
Hyeon Hwan Hwang
Assistant Managing Director · since 2025
Se Min Jang
Assistant Managing Director
Hyeong Seon Kim
Assistant Managing Director · since 2024
Yu Sik Kim
Assistant Managing Director · since 2023
IPO date
Dec 15, 1999
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT